Cite
HARVARD Citation
Cao, C. et al. (2021). Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta‐analysis. Pharmacology research & perspectives. 9 (4), p. n/a. [Online].